Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-11: IV fixed-dose tiragolumab + atezolizumab in advanced solid tumors
2023-508489-14-00Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab and atezolizumab in Nonhematologic neoplasms, esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and 8 more, sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Sep 2023; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Nonhematologic neoplasmsesophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2023-508489-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508489-14-00.